Vaxart (VXRT) Proxy filing summary

Executive summary

• Focus on the upcoming 2026 Annual Meeting of Stockholders, with solicitation of proxies for board elections.

• Emphasis on the company's proprietary oral vaccine platform and ongoing clinical programs targeting coronavirus, norovirus, influenza, and HPV.

• Forward-looking statements highlight expectations for clinical trial results, regulatory approvals, and strategic partnerships.

Voting matters and shareholder proposals

• Shareholders are urged to vote "FOR" all six director nominees on the WHITE proxy card and to withhold votes on shareholder nominees.

• Two newest independent directors, James Breitmeyer and Kevin Finney, publicly endorse the current board's experience and leadership.

Board of directors and corporate governance

• James Breitmeyer and Kevin Finney joined as independent directors, reinforcing board independence and expertise.

• Board composition is positioned as critical to advancing the company's strategic direction and scientific innovation.